Results for tag: "Betalutin"

The Betalutin market is a subset of the larger lymphoma drug market, focusing on the development and commercialization of Betalutin, a novel targeted therapy for the treatment of relapsed or refractory non-Hodgkin lymphoma. Betalutin is a monoclonal antibody that binds to a specific protein on the surface of cancer cells, triggering an immune response that kills the cancer cells. Betalutin is the first of its kind to be approved by the US Food and Drug Administration (FDA) for the treatment of relapsed or refractory non-Hodgkin lymphoma. The Betalutin market is highly competitive, with several major pharmaceutical companies vying for market share. Companies in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead Sciences, Merck, Novartis, and Pfizer. Show Less Read more